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Delivery of health care at the end of life in cancer
patients of four swiss cantons: a retrospective
database study (SAKK 89/09)
Klazien W Matter-Walstra1,2*†, Rita Achermann3†, Roland Rapold3, Dirk Klingbiel2, Andrea Bordoni4, Silvia Dehler5,
Gernot Jundt6, Isabelle Konzelmann7, Kerri M Clough-Gorr8,9, Thomas D Szucs1,3, Matthias Schwenkglenks1†
and Bernhard C Pestalozzi10†
Abstract
Background: The use of cancer related therapy in cancer patients at the end-of-life has increased over time in
many countries. Given a lack of published Swiss data, the objective of this study was to describe delivery of health
care during the last month before death of cancer patients.
Methods: Claims data were used to assess health care utilization of cancer patients (identified by cancer registry
data of four participating cantons), deceased between 2006-2008. Primary endpoints were hospitalization rate and
delivery of cancer related therapies during the last 30 days before death. Multivariate logistic regression assessed
the explanatory value of patient and geographic characteristics.
Results: 3809 identified cancer patients were included. Hospitalization rate (mean 68.5%, 95% CI 67.0-69.9) and
percentage of patients receiving anti-cancer drug therapies (ACDT, mean 14.5%, 95% CI 13.4-15.6) and radiotherapy
(mean 7.7%, 95% CI 6.7-8.4) decreased with age. Canton of residence and insurance type status most significantly
influenced the odds for hospitalization or receiving ACDT.
Conclusions: The intensity of cancer specific care showed substantial variation by age, cancer type, place of
residence and insurance type status. This may be partially driven by cultural differences within Switzerland and the
cantonal organization of the Swiss health care system.
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Background
Several studies in the United States and Europe have
shown that the use of anticancer treatments at the end-
of-life has increased considerably [1-4]. To a substantial
extent, treatment patterns seem to depend on medical as
well as nonmedical (hospital type, socio-demographic)
factors [5-7]. In addition, studies in health services re-
search have shown that the delivery of health care may
be quite unequal between patient groups and/or in dif-
ferent geographic areas, despite existing guidelines and
standard procedures [8-10]. Non-cancer related studies
for Switzerland have revealed large variations in health
care utilization among geographic regions [11-14]. How-
ever, to the best of our knowledge, no study on the deliv-
ery of health care at the end-of-life of cancer patients
has been performed in Switzerland.
The implications of time trends and diversity in treat-
ment patterns at the end of life are unknown. Irrespect-
ive of this, the use of anticancer treatments is regarded
as an important descriptor of end-of-life care for cancer
patients [15-17]. With rising health care costs, ever new
expensive anticancer drugs being released and a persist-
ent focus of political attention the necessity to provide
independent data on the use of resources at the end of
life is self-evident.
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The development of large electronic databases by health
insurance companies, cancer registries and hospitals during
the last decades has facilitated research in this direction
considerably [3,18-20]. The combination of claims data-
bases, cancer registries and patient records has previously
been used to study time trends in chemotherapy use at the
end-of-life [2,19,21]. Swiss cancer registries are organized
on a cantonal basis and are lacking in several cantons
(2010 data coverage approximately 70% of the national
population). Large (national) or smaller regional health in-
surance companies provide compulsory health insurance
in Switzerland.
We have studied patterns of care in recently deceased
patients to gain initial insight and provide urgently
needed information on current end-of-life care for can-
cer patients in Switzerland. Data from one large health
insurance company were combined with data from four
cantonal cancer registries.
Given a lack of published Swiss data, the first main ob-
jective of the study was to describe delivery of health
care during the last 30 days before death in terms of
therapies used and hospitalization frequencies, for all
cancers combined and for major cancer types (lung,
breast, prostate, colon or hematological cancers). The
second main objective was to assess the magnitude and
significance of effects of demographic, geographic and
insurance coverage-related factors on the above named
indicators. The study was not designed for and does not
intend to make any value judgments on the appropriate-
ness of the health care provided.
Methods
Study population
This retrospective study included patients 20 years or
older at time of cancer diagnosis who died between 2006
and 2008, lived in one of the participating Swiss cantons,
and were customers of Helsana Group insurance com-
pany for at least one year before death. Eligible patients
were identified by deterministic linkage of the Helsana
health insurance claims data with cancer incidence data
from four cantonal cancer registries, Basel (BL/BS), Ti-
cino (TI), Valais (VS) and Zürich (ZH). All data were
linked using the SAS® based “The Link King”© software
[22]. It was not possible to obtain informed consent
from relatives of the deceased patients. Therefore, priv-
acy protecting linkage procedures were utilized and all
patient data was anonymized. The study was approved
by the ethics committees of the BL/BS (Ethikkommis-
sion beider Basel), TI (Comitato etico cantonale), VS
(Commission Cantonale Valaisanne d’Ethique Médicale)
and ZH (Kantonale Ethikkommission Zürich) and by an
expert committee responsible for data protection issues
at the Swiss Federal Office of Public Health.
Data sources
Helsana insurance claims
The Helsana Group (www.Helsana.ch) is one of the lar-
gest Swiss health insurance companies and provided
health insurance to 1,28 million customers (about 20%
of the Swiss population) in 2006. Health insurance is
compulsory in Switzerland for every resident and is pro-
vided by up to 90 different insurance companies on a
non-profit basis. It covers events of general medical ill-
ness and pregnancy. Federal law uniformly defines the
reimbursement package. Through voluntary supplemen-
tary health insurance, coverage for additional health care
services can be obtained. Unlike benefits from compulsory
insurance, benefits from supplementary health insurance
differ depending on the product chosen. Supplementary
insurance can be purchased at the same or another health
insurance company. In our study we only took into ac-
count the services covered by the compulsory health insur-
ance. The Helsana data provided detailed information on
all outpatient medical services provided. For inpatient ser-
vices no such details were available. The Helsana database
is not publicly available and permission to use the data
was given by the Helsana directorate and approved by the
above-listed ethics committees and expert committee.
Cancer registry incidence data
In Switzerland there is no national cancer registry and
only 14 out of 26 cantons had a cantonal cancer registry
in 2010. All cantons with a cancer registry were con-
tacted by the National Institute for Cancer Epidemiology
and Registration (NICER) and asked to take part in the
study. The registries of four cantons agreed to partici-
pate: BS/BL (urbanization rate 90%, language German,
one university hospital), TI (urbanization rate 82%, lan-
guage Italian, no university hospital), VS (urbanization
rate 53%, language German and French, no university
hospital) and ZH (urbanization rate 90%, language
German, one university hospital) [23]. The cancer regis-
tries provided information on cancer diagnosis (ICD-10)
and the exact date of death.
Hospital data
Swiss claims data relating to inpatient episodes in acute
care hospitals do not contain sufficient detail on the
treatments or diagnostic procedures performed. There-
fore, this information was collected from patient records
in the treating hospitals for all patients with a hospital
stay during the last 30 days before death (including
those who were admitted before day 30 before death but
discharged within 30 days before death).
Outcomes and covariates
Primary endpoints of this study were indicators of the
intensity of care delivered to cancer patients in the last
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30 days before death, defined as hospitalization rate, ad-
ministration of any in- or out-patient ACDT (for defin-
ition see Additional file 1: Table S1. Anti-cancer drug
therapy medication), administration of any in- or out-
patient RT and any cancer related therapy (ACDT and/
or RT). These endpoints were set in relation to several
potential explanatory variables. These included patient
characteristics, such as birthdate (source Helsana), death
date (source cancer registries), gender (source Helsana),
cancer diagnosis (source cancer registries) and type of
health insurance (source Helsana), as well as geo-
graphic characteristics, such as canton of residence
(source Helsana) and borough type (source Federal Office
of Statistics, Helsana).
For prescription drugs, anatomical therapeutic chem-
ical (ATC) codes were available [24]. Outpatient diag-
nostic tests and therapies were coded according to
TARMED, the Swiss tariff system for medical services
provided to outpatients [25]. A separate coding system
existed for laboratory tests (http://www.bag.admin.ch/al).
The date of each outpatient test and treatment were
known. For some claims, not all details were electronically
accessible but scanned copies of these invoices were avail-
able and were reviewed from an electronic archive. All in-
formation on ACDT, RT or diagnostic tests performed
during the last 30 days before death was recorded. The
same information was retrieved from patient records for
those patients with a hospitalization within the last 30 days.
Cancer diagnoses were grouped into six groups ac-
cording to the International Statistical Classification of
Diseases and Related Health Problems 10th Revision
(ICD-10) codes: colon (ICD-10 = C18.x), hematologic
(ICD-10 = C81.x – C96.x), lung (ICD10 = C34.x), breast
(ICD-10 = C50.x), prostate (ICD-10 = 61.x) and all others
combined (to obtain a meaningful group size). Based on
Helsana data, information on supplementary insurance for
hospitalization (hospital supplementary insurance HSI)
was categorized into three categories. These were obliga-
tory health insurance only (i.e. no HSI patients can only
be hospitalized on a general ward in predefined hospitals
in their canton of residence, exception only when a certain
service is not available in the canton of residence); basic
supplementary hospital insurance (ECO) with free choice
of hospital all over Switzerland (general ward only); and
semi-private or private supplementary hospital insurance
(SP + P) with free choice of hospital all over Switzerland
and coverage of the additional cost for a double or single
room. Two urbanization types for boroughs were used:
city (including agglomeration) and rural, as defined by the
Swiss Federal Office of Statistics.
Reason for hospitalization
For all included patients hospitalized during the last
30 days before death, the reason for hospitalization was
defined as cancer related (CRH) or non-cancer related
(NCRH). CRH included patients who had a primary ad-
mission diagnosis indicative of cancer, and/or had cancer
related symptom(s) or diseases, or had a non-cancer re-
lated reason of admission but had an ongoing active
cancer as described in the patient history. NCRH in-
cluded patients where the diagnosis of cancer was men-
tioned in the patients’ medical history but without an
indication of currently active disease. Cause of death in-
formation was not systematically available for all in-
cluded patients.
Power
Power calculation for the primary endpoints have con-
sidered a range of scenarios for the design parameters of
a logistic regression: the expected odds ratio (OR), the
percentage of patients reaching the endpoint of interest (E)
in the reference class (for example canton =ZH), and the
squared multiple correlation coefficient ρ2 1.23…p also known
as R2 [26] when the main variable (canton) is regressed on
the other independent variables in the regression model. For
most scenarios (e.g. for OR ≥ 1.5, E ≥ 20%, and R2 ≤ = 0.2)
the expected power was ≥ 80%.
Statistical analysis
Endpoints, patient characteristics and potential covari-
ates were described using frequencies and percentages in
the case of categorical variables. For continuous vari-
ables, mean, standard deviation and range were used.
The impact of age on the endpoint variables was primar-
ily assessed using age groups (<45, 45-49, 50-54 etc. up
to >94 years [27]), in order to detect non-linear associa-
tions. Where such non-linear associations were detected,
age was divided into splines based on the segmented
polynomials approach [28,29].
Multivariate logistic regressions were performed using
a stepwise method to select statistically significant ex-
planatory variables. For consideration to enter the model
as a co-variant univariate a P-value threshold of <0.1
had to be reached. To stay in the multivariate model a
threshold of P <0.05 was set. The following variables
were tested in the model: age at death (using age splines
where required), gender, cancer type (colon, hematologic,
lung, breast, prostate and other), insurance status (no HSI,
ECO, SP + P), canton of residence (BS/BL, VS, TI, ZH),
and borough type (urban, rural). For the outcomes of
ACDT, RT and ACDT and/or RT, a covariate representing
reason for hospitalization (comprising the categories no
information available (NoInf)), CRH, NCRH) was added
to the model as a technical control variable. In addition,
all possible interactions between these variables were
tested. Goodness of fit of logistic regression models was
tested with the Hosmer and Lemeshow Goodness-of-Fit
Test [30]. Parameter estimates and OR were calculated
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including Walds 95% confidence intervals (95% CI).
P-values were considered significant if < 0.05, two-sided.
Given the explorative nature of this study, there was no
adjustment for multiple testing. All statistics were per-
formed with SAS®, version 9.2.
Results
Cancer patient identification and inclusion
Between 2006 and 2008 the Helsana database contained
47,769 deceased customers who had been insured for at
least 1 year before death. After linking these persons to
the four cancer registries 3,809 patients were identified as
being eligible and were included in the study (see Figure 1).
The distribution of patients over the four cantons differed
slightly from the expected distribution calculated accord-
ing to the cause of death statistics (www.bfs.admin.ch) and
the percentage Helsana insured population (BL/BS = 9.8%
expected 12.2%, TI = 23.8% expected 17.2%, VS = 9.4% ex-
pected 8.8%, ZH = 55.3% expected 61.8%, see Table 1).
Hospital in-patient data collection
During the last 30 days before death 2,608 (68.5%, see
Table 2) of the patients were hospitalized in 49 different
acute care hospitals. Data collection for in-patient re-
source use was done in 37 hospitals, 3 hospitals refused
chart review and 9 hospitals were not contacted because
they would only have provided information on less than
10 patients. Overall, in-patient information was available
for 2,494 (96%) of the hospitalized patients. Of these pa-
tients, 2,086 (83.6%) had a cancer related hospitalization.
Descriptive results for the last 30 days before death
Among the 3,809 patients included there were slightly
more male (52.7%) than female patients. Of the specified
cancer diagnosis groups most patients were diagnosed
with lung cancer (14.6%) followed by prostate cancer
(10.4%, see Table 1). The mean age at death of all pa-
tients was 75.5 years.
A total of 2,608 (68.5%; 95% CI = 67.0-69.9) patients
were hospitalized (see Table 2 for descriptive results). Of
the hospitalized patients 80% (61%; 95% CI = 59.5-62.7
of all patients) died while in hospital. There was a differ-
ence in hospitalization frequency of almost 10% between
male (72.9%, 95% CI = 71.0-74.9) and female patients
(63.5%, 95% CI =61.3-65.7), and between patients with in-
surance type no HSI (63.0%, 95% CI = 60.3-65.7) or SP + P
(73.6%, 95% CI = 71.0-76.3). Patients with lung cancer
(76.1%, 95% CI = 72.6-79.7) had an almost 20% higher
hospitalization frequency then patients with breast cancer
(58.2%, 95% CI = 53.2-63.2). The canton with the high-
est hospitalization frequency was BS/BL (74.1%, 95%
CI = 69.7-78.5) and the canton with the lowest fre-
quency was VS (58.4%, 95% CI = 53.3-63.5).
In- and/or outpatient ACDT was given to 14.5% (95%
CI = 13.4-15.6) of all patients. High proportions of
Figure 1 Study patients.
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ACDT use were seen in patients with lung cancer
(20.3% (95% CI = 16.9-23.6), SP + P insured patients
20.5% (95% CI = 18.0-22.9), and in patients living in the
canton TI (18.3% (95% CI = 15.8-20.7). In patients with a
CRH ACDT use was 22.6% (95% CI = 20.8-24.4).
Overall 7.7% (95% CI = 6.7-8.4) of the patients received
in- and/or outpatient RT. Of all cancer types lung cancer
patients received the most RT (13.5%, 95% CI = 10.6-
16.3). Of all cantons, TI was the one with the highest
ACDT frequency, but had the lowest RT use (5.7%, 95%
CI = 4.2-7.2).
The combined ACDT and/or RT use proportion was
20.3% (95% CI = 19.0-21.6). Far above this average figured
lung cancer patients (31.1%, 95% CI = 27.2-34.9) and
patients with insurance type SP + P (26.3%, 95% CI = 23.6-
28.9). Much lower use was observed in patients living in
the canton VS (13.2%, 95% CI = 9.7-16.7).
Age effects
Hospitalization admission and ACDT use were strongly
age-dependent; a linear decrease was observed after age
65 years. For RT a linear decrease was observed after the
age of 75 (see Figure 2). Therefore, spline techniques
were used in the multivariate logistic regression models
to model the separate age effects for patients below or
above 65 years old (models of hospitalization, ACDT use
and ACDT and/or RT use) or for patients below or
above 75 years old (model of RT use).
Multivariable logistic regression
The multivariate logistic regression of hospitalization
rates showed significant effects for the variables age,
gender, cancer type, canton, borough type and insurance
type (see Additional file 2: Table S2, and Figure 3). Males
had a significantly higher odds of hospitalization than
females (at age = 77, OR =1.38, 95% CI = 1.17-1.64).
Compared to lung cancer patients, breast (OR = 0.66,
95% CI = 0.48-0.90) and prostate (OR = 0.69, 95% CI =
0.51-0.94) cancer patients were significantly less likely
to be hospitalized. At the cantonal level BS/BL (OR = 1.38,
95% CI = 1.03-1.72) and TI (OR = 1.21, 95% CI = 1.01-
1.44) showed significantly higher odds of hospitalization
than ZH. In contrast VS (OR = 0.74, 95% CI = 0.58-0.97)
and patients living in rural areas (OR = 0.75, 95% CI =
0.58-0.99) were less likely to be hospitalized. An OR of
1.40 (at age = 77, 95% CI = 1.16-1.69) was seen for patients
Table 1 Descriptive statistics of demographic and geographic information
All BS/BL TI VS ZH
Overall (expected) N = 3809 (2869) N =378 (350)
9.8% (12.2%)
N =926 (493)
23.8% (17.2%)
N =363 (252)
9.4% (8.8%)
N =2142 (1773)
55.3% (61.8%)
Gender Male 52.7% 57.1% 55.0% 55.4% 50.4%
Female 47.3% 42.9% 45.0% 44.6% 49.6%
Cancer diagnosis Colon 7.9% 8.5% 7.8% 5.5% 8.3%
Hematologic 6.7% 4.8% 9.1% 1.4% 6.9%
Lung 14.6% 14.6% 13.3% 17.1% 14.8%
Breast 9.9% 9.3% 8.3% 7.2% 11.2%
Prostate 10.4% 7.9% 9.1% 8.3% 11.7%
Other 50.5% 55.0% 52.5% 60.6% 47.1%
Hospital supplementary insurance status No HSI 32.1% 35.7% 26.5% 38.8% 32.8%
ECO 39.9% 34.9% 45.0% 50.2% 36.8%
SP + P 28.0% 29.4% 28.5% 11.0% 30.4%
Borough type City + Agglomeration 91.9% 95.8% 89.1% 65.0% 97.0%
Rural 8.1% 4.2% 10.9% 35.0% 3.0%
Age Mean 75.5 75.3 76.8 76.2 74.8
Median 77.3 77.0 78.6 78.0 76.8
SDEV 12.2 11.6 11.8 12.5 12.3
Range 23-102 40-102 25-101 29-102 23-102
Time from first diagnosis until death (years) Mean 4.15 4.60 3.02 4.64 4.49
Median 2.0 2.0 2.0 2.0 2.0
SDEV 5.28 6.17 5.08 5.98 5.76
Range <1 year-27 <1 year-27 <1 year-12 <1 year-19 <1 year-27
Legend: Hospital supplementary insurance status: no HSI = no hospital supplementary insurance, ECO = basic hospital supplementary insurance, SP + P = semi
private and private hospital supplementary insurance (2 or single bed room), SDEV = standard deviation.
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with insurance type SP + P compared to patients without
a HSI. There was significant interaction between age and
gender, indicating that with increasing age the probability
to be hospitalized decreased significantly more for female
than male patients. In addition, significant interaction be-
tween age and insurance type implied that with increasing
age the probability to be hospitalized decreased signifi-
cantly more for ECO than for no HSI insured patients
while the hospitalization probability for SP + P insured pa-
tients decreased (not significantly) less than for no HSI in-
sured patients.
Receiving ACDT was significantly influenced by age,
gender, cancer type, canton, and the control variable
representing reason for hospitalization. The highest OR
were seen for breast cancer (OR = 1.87, 95% CI = 1.08-
3.22, at age = 77) compared to lung cancer patients, can-
ton TI versus canton ZH (OR = 1.56, 95% CI = 1.24-2.00)
and SP + P insured compared to no HSI (OR = 1.82, 95%
CI = 1.40-2.38, at age = 63, see Figure 3). There was sig-
nificant interaction between cancer type and age, indi-
cating that for some cancer types (namely, hematologic
and other cancers), with increasing age, the probability
to receive ACDT decreased significantly less than for
other cancer types. In addition, significant interaction
between insurance type and age implied that in younger
patients (<65 years) the probability to receive ACDT de-
creased significantly slower with increasing age for SP +
P insured patients then no HSI insured patients, while
this difference did no longer exist for older patients
(>65 years).
Receiving RT was only significantly influenced by age
and reason for hospitalization. Furthermore a significant
interaction between cancer type and age was observed.
At age = 70 breast (OR = 0.47, 95% CI = 0.27-0.81), colon
(OR = 0.48, 95% CI = 0.27-0.85), hematological (OR = 0.42,
95% CI = 0.23-0.78) and other (OR = 0.50, 95% CI = 0.36-
0.69) cancer patients received significantly less likely RT
than lung cancer patients (see Figure 3). With increasing
age the odds of receiving RT decreased less for lung can-
cer patients then all other patients.
For the endpoint of any cancer related therapy (ACDT
and/or RT), cancer type and insurance type were
Table 2 Descriptive statistics of clinical information
During last month before death Hospitalized
n/% (95% CI)
Cancer drug therapy
n/% (95% CI)
Radiotherapy
n/% (95% CI)
Cancer drug and/or
radiotherapy n/% (95% CI)
ALL (n = 3809) Died in
Hospital (n = 2327, 61.1%)
2608/68.5 (67.0 – 69.9) 552/14.5 (13.4 – 15.6) 293/7.7 (6.7 – 8.4) 773/20.3 (19.0 – 21.6)
Gender Male (n = 2006) 1463/72.9 (71.0 – 74.9) 310/15.4 (13.8 – 17.0) 175/8.7 (7.5 – 10.0) 440/21.9 (20.1 – 23.7)
Female (n = 1803) 1145/63.5 (61.3 – 65.7) 244/13.5 (12.0 – 15.1) 114/6.3 (5.1 – 7.4) 334/18.5 (16.7 – 20.3)
Cancer diagnosis Colon (n = 301) 194/64.5 (59.0 – 69.9) 43/14.3 (10.3 – 18.2) 19/6.3 (3.6 – 9.1) 56/18.6 (14.2 – 23.0)
Hematologic (n = 255) 187/73.3 (67.9 – 78.8) 48/18.8 (14.0 – 23.6) 16/6.3 (3.3 – 9.3) 56/22.0 (16.9 – 27.0)
Lung (n = 557) 424/76.1 (72.6 – 79.7) 113/20.3 (16.9 – 23.6) 75/13.5 (10.6 – 16.3) 173/31.1 (27.2 – 34.9)
Breast (n = 378) 220/58.2 (53.2 – 63.2) 68/18.0 (14.1 – 21.9) 24/6.3 (3.9 – 8.8) 86/22.8 (18.5 – 27.0)
Prostate (n = 395) 225/64.6 (59.8 – 69.3) 33/8.4 (5.6 – 11.1) 32/8.1 (5.4 – 10.8) 61/15.4 (11.9 – 19.0)
Other (n = 1923) 1328/69.1 (67.0 – 71.1) 249/12.9 (11.4 – 14.4) 123/6.3 (5.3 – 7.4) 340/17.7 (16.0 – 19.4)
Hospital
supplementary
insurance status
No HSI (n = 1224) 771/63.0 (60.3 – 65.7) 135/11.0 (9.3 – 12.8) 147/6.5 (5.1 – 7.8) 200/16.3 (14.2 – 18.3)
ECO (n = 1520) 1053/69.3 (67.0 – 71.6) 201/13.2 (11.5 – 14.9) 116/7.6 (6.3 – 9.0) 293/19.3 (17.4 – 21.3)
SP + P (n = 1065) 782/73.6 (71.0 – 76.3) 218/20.5 (18.0 – 22.9) 93/8.7 (7.0 – 10.4) 280/26.3 (23.6 – 28.9)
Canton of residence BS/BL (n = 378) 280/74.1 (69.7 – 78.5) 50/13.2 (9.8 – 16.6) 32/8.5 (5.7 – 11.3) 76/20.1 (16.1 – 24.1)
TI (n = 926) 654/70.6 (67.7 – 73.6) 169/18.3 (15.8 – 20.7) 53/5.7 (4.2 – 7.2) 208/22.5 (19.8 – 25.2)
VS (n = 363) 212/58.4 (53.3 – 63.5) 31/8.5 (5.7 – 11.4) 21/5.8 (3.4 – 8.2) 48/13.2 (9.7 – 16.7)
ZH (n = 2142) 1462/68.3 (66.3 – 70.2) 304/14.1 (12.7 – 15.6) 183/8.5 (7.3 – 9.7) 441/20.6 (18.9 – 22.3)
Borough type City + Agglomeration
(n = 3501)
2419/69.1 (67.6 – 70.6) 515/14.7 (13.4 – 16.0) 226/7.6 (6.6 – 8.4) 718/20.5 (19.1 – 21.8)
Ruraly (n = 308) 189/61.4 (55.9 – 66.8) 37/12.0 (8.4 – 15.6) 23/7.5 (4.5 – 10.4) 57/18.5 (14.2 – 22.8)
Patient
hospitalization/
chart information
No information* (n = 1337) 79/5.9 (4.6 – 7.2) 45/3.4 (2.4 – 4.3) 116/8.7 (7.2 – 10.2)
Cancer related hosp.
(n = 2068)
467/22.6 (20.8 – 24.4) 234/11.3 (9.9 – 12.7) 643/31.1 (29.1 – 33.1)
Not cancer related hosp.
(n = 404)
6/1.5 (0.3 – 2.7) 9/2.2 (0.8 – 3.7) 14/3.5 (1.7 – 5.2)
Legend: *Not hospitalized in last month before death or patient dossier not reviewed. Hospital supplementary insurance status: no HSI = no hospital supplementary
insurance, ECO = basic hospital supplementary insurance, SP+ P = semi private and private hospital supplementary insurance (2 or single bed room).
Matter-Walstra et al. BMC Cancer 2014, 14:306 Page 6 of 11
http://www.biomedcentral.com/1471-2407/14/306
significant predictors. Most prominent was the effect of
insurance type with an OR of 1.61 (95% CI = 1.29-2.02)
for SP + P insured compared to no HSI patients (see
Figure 3). For this endpoint a significant interaction be-
tween gender and reason for hospitalization existed,
implying that especially for CRH patients male had a
higher probability to receive any type of cancer therapy.
Discussion
Probabilities of hospitalization, ACDT use, RT use, and
use of any cancer related therapy were generally higher
in men than in women. Hospitalization frequency and
therapy intensity decreased strongly with age. For
hematologic (and other) cancers observed differences in
proportions of ACDT and RT use depended more on
age than for the remaining cancer types. Lung cancer
patients received more ACDT and RT than all other pa-
tients while breast cancer patients at a higher age were
the most likely to receive ACDT. In terms of cantonal
differences, patients in canton TI were most likely to re-
ceive ACDT but least likely to receive RT. As a conse-
quence, there was no significant difference between
Figure 2 Age effects on hospitalization and therapies. Legend: •-• = proportion of patients with indication, dark grey area = 95% confidence
interval on proportion, light grey bars = number of patients per age group, ---- =mean proportion across all age groups.
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cantons in terms of administration of any cancer related
therapy. For all endpoints, the canton VS generally showed
the lowest use but only the probability of hospitalization
was significantly lower than in ZH, the reference canton.
Hospitalization frequencies were lower in rural areas. In-
surance type had a strong effect on all endpoints; patients
with insurance type SP + P were hospitalized significantly
more often and were significantly more likely to receive
cancer related therapies (ACDT, ACDTand/or RT).
The percentage of patients dying while hospitalized
(61%) was much higher than percentages reported for
Belgium and the Netherlands (29% and 19%, respect-
ively, excluding patients suffering sudden death) [31] or
the USA (38%) [32]. One reason for this finding may be
a low availability of hospice care facilities in Switzerland.
On the other hand, many acute-care hospitals have pal-
liative care wards to which end-of-life patients may be
transferred. We were not able to distinguish the types of
wards where patients stayed and therefore the percent-
age of patients who died in a true acute-care setting may
be substantially lower than 61%. Overall the observed
percentage of patients receiving ACDT during the last
month before death (14.5%) is in line with observations
made by Earle et al. (USA, 14-18% in the last two weeks
before death) [2]), Emanuel et al. (USA, 9% in the last
month before death [6]) or Kao et al. (Australia, 18%
Figure 3 Multivariate logistic regression. Legend: * not significant > not included in the final multivariate model.
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within the last month before death [7]). The percentage
patients receiving radiotherapy during the last month
before death (7.7%) was also similar to the one observed
by others [33,34].
Cantonal differences may be partially caused by di-
verse cultural attitudes of treating physicians as well as
patients, which was also observed in other Swiss health
services research studies [11-14]. The highest probabilities
of hospitalization were seen for patients with a SP + P in-
surance. This result might hint at a financial incentive on
the part of the care providers to hospitalize or to treat pa-
tients with a supplementary insurance status. On the other
hand this increased utilization may be demand–driven by
more demanding patients having paid for a more expen-
sive insurance.
Cancer type and age effects
Cancer type did influence several endpoints, with lung
cancer patients being most likely to be hospitalized or to
receive ACDT or RT. This finding is not surprising given
the greater likelihood of lung cancer patients to experi-
ence dyspnea and other severe symptoms in their final
disease stages [35]. Most of these differences were to be
expected and are thought to be in accordance with the
clinical practice for these cancers. The observed de-
crease in hospitalization probability and ACDT or RT
use with increasing age was also to be expected and is in
accordance with results from other studies [2,6].
Whether more or less frequent hospitalization or de-
gree of ACDT/RT treatment are indicative of under- or
over-treatment, and whether or not they are more
strongly influenced by supply side or demand side fac-
tors, cannot be answered by this study. Unfortunately,
we cannot differentiate between ACDT or RT given with
a curative or a palliative intent. High use may indicate
appropriate palliative care and should not primarily be
interpreted as “aggressive” care, a term used by other au-
thors [2,4,32,36]. Conversely, low use might indicate ap-
propriate abstention from treatment but might as well
hint at under-treatment. It is not possible to make the
distinction with these data.
Strengths and weakness
This study has some weaknesses. One limitation is that
we have no reliable information on the cause of death
for those patients not hospitalized during the last month
before death. This may have led to an underestimation
of ACDT and RT use due to the possibility of inclusion
of some patients in the denominator who may not have
had an active cancer disease at the time of death.
Another limitation is that the Helsana database may
have had missing information on ACDT or RT use (for
example missing ATC codes) which furthermore may
lead to an underestimation of these outcomes. Also the
information on HSI was only available for those patients
who had this insurance with Helsana. For those patients
with a supplementary insurance at another insurance
company, this information was not available.
In addition, these findings are not generalizable to all
of Switzerland for several reasons. The study is based on
data from only one insurance company (albeit one of the
largest in Switzerland with a market share of about
20%). Also Helsana on average serves an older popula-
tion then the general Swiss population [11], and intensity
of care decreases with age, so use of ACDT or RT in
Switzerland may be higher than reported here. Further-
more data were available only from four out of 14 cantons
with a cancer registry representing a small proportion of
the national Swiss population. Especially the absence of
data from purely French speaking cantons implies a poten-
tially important knowledge gap, as these cantons represent
a culturally distinct population with a different medical be-
havior and generally higher health care utilization [12].
The major strength of this study is that it provides an
initial assessment of previously unavailable data and
confirms a substantial degree of variation in end-of-life
care for cancer patients in Switzerland. This implies a
need for further research. The study also demonstrates
the feasibility of Swiss research projects in the field of
cancer-related Health Services Research that require
linkage of data from different sources. It may serve as a
model and may encourage further larger scale investiga-
tions in the field of cancer and other diseases, using
similar approaches to combine several data sources.
Next steps might be to implement data from more in-
surance companies as well as more cantons. In addition
cost assessments may complement gained insight and
help to better understand and guide the oncology com-
munity in providing cancer care at the end-of-life.
Conclusion
This is the first larger scale Swiss study of patterns of
care at the end-of-life of cancer patients. Data from four
Swiss cantons show that the intensity of cancer specific
care during the last month before death varies with age,
cancer type, and place of residence as well as insurance
type. The existence of such differences within a small
country such as Switzerland may be partially driven by
cultural differences on the side of physicians as well as
patients and may be supported by the predominantly
cantonal organization of the Swiss health care system.
Conclusions regarding quality-of-care issues are not pos-
sible on the basis of this study, but would be of great im-
portance in future research.
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